<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04831918</url>
  </required_header>
  <id_info>
    <org_study_id>H-31</org_study_id>
    <nct_id>NCT04831918</nct_id>
  </id_info>
  <brief_title>Cemented Acetabular Cups Clinical Study</brief_title>
  <official_title>A Prospective Clinical Study Evaluating Clinical, Radiographic And Patient-Reported Outcomes Of THA With Cemented Acetabular Cups</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Limacorporate S.p.a</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Limacorporate S.p.a</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study has the aim to evaluate clinical, radiographic, patient-reported outcomes&#xD;
      of total hip arthroplasty with the implant of Mueller cemented acetabular cups up to 2 years&#xD;
      after surgery, in order to assess the performance of the device. Furthermore, it aims to&#xD;
      collect short-term survivorship of the implant and the incidence of early complications.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">December 22, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 22, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical progression of Harris Hip Score (HHS) from baseline to 2 years after surgery</measure>
    <time_frame>2 years Follow up</time_frame>
    <description>HHS ranges from 0 to 100, being 0 the worst and 100 the best conditions. HHS is reported as 90-100 for excellent results, 80-90 for good, 70-79 for fair, 60-69 for poor, and below 60 for a failed result. The outcome is considered satisfactory for values over 80</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiographic evaluation and stability assessment of the implant up to 2 years FU</measure>
    <time_frame>6 weeks, 1 year and 2 years FU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical progression of HOOS up to 2 years FU, compared to the baseline</measure>
    <time_frame>6 weeks, 1 year and 2 years FU</time_frame>
    <description>Hip disability and osteoarthritis outcome score (HOOS) is a patient-reported outcome measurement, that ranges from 0 to 100, with 100 indicating no symptoms and 0 indicating extreme symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in TUG from preoperative up to 2 years FU</measure>
    <time_frame>6 weeks, 1 year and 2 years FU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical progression of HHS up to 1 year FU, compared to the baseline</measure>
    <time_frame>6 weeks, 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implant survivorship (Kaplan-Meier estimate) at 2 years after surgery</measure>
    <time_frame>2 years FU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of device-related AE/SAE up to 2 years of follow-up</measure>
    <time_frame>6 weeks, 1 year and 2 years FU</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Total Hip Arthroplasty</condition>
  <arm_group>
    <arm_group_label>Mueller cemented cups</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo total hip arthroplasty with the implant of the Mueller cemented cup as acetabular component.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mueller cemented cups</intervention_name>
    <description>Patients undergo total hip arthroplasty with the implant of Mueller cemented cups</description>
    <arm_group_label>Mueller cemented cups</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patient has participated in the Informed Consent process and has signed the&#xD;
             Informed Consent form previously approved by the Ethics Committee;&#xD;
&#xD;
          2. The patient diagnosis is one or more of the following:&#xD;
&#xD;
               -  Patient with advanced articular destruction generated by primary degenerative or&#xD;
                  post-traumatic arthrosis or rheumatoid arthritis;&#xD;
&#xD;
               -  Patient with avascular necrosis of the femoral head or fracture of the femoral&#xD;
                  neck;&#xD;
&#xD;
               -  Patient with congenital or acquired deformity;&#xD;
&#xD;
               -  Patient with failures of previous operations, like osteosynthesis, articular&#xD;
                  reconstruction, arthrodesis, hemi-arthroplasty or total arthroplasty.&#xD;
&#xD;
          3. The patient is willing and able to complete scheduled follow-up evaluations as&#xD;
             described in the Patient Information Sheet;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The patient should be excluded from the study if he/she meets any of the following&#xD;
        criteria, which reflect the cemented acetabular cup contraindication for use:&#xD;
&#xD;
          1. Acute or chronic infections, local or systemic infections;&#xD;
&#xD;
          2. Serious muscular, neurological or vascular diseases affecting the concerned limb;&#xD;
&#xD;
          3. Any concomitant disease and dependence that might affect the implanted prosthesis;&#xD;
&#xD;
          4. Allergy to material;&#xD;
&#xD;
          5. Metal-on-metal systems: patients with renal impairment.&#xD;
&#xD;
          6. Patient's age&lt;18&#xD;
&#xD;
          7. Female patients who are pregnant, nursing, or planning a pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luca Marega</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale San Camillo di Trento</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gaia Pacassoni</last_name>
    <phone>T +39 366 6248631</phone>
    <email>gaia.pacassoni@limacorporate.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ospedale San Camillo di Trento</name>
      <address>
        <city>Trento</city>
        <state>TN</state>
        <zip>38122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Luca Marega</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlo Marega</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniele Lamberti</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 1, 2021</study_first_submitted>
  <study_first_submitted_qc>April 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2021</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cemented acetabular cup</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

